Printer Friendly

Genzyme gets European approval for treating CKD patients with Renvela; positive opinion for marketing Mozobil.

Genzyme Corporation, Cambridge, MA, announced the European Commission (EC) has approved Renvela for the control of serum phosphorus in patients with chronic kidney disease (CKD). The approval includes patients not on dialysis with serum phosphorus levels >1.78 mmol/L, and covers both the tablet and powder formulations.

Renvela is a next generation version of Renagel, a calcium-free metal free, non-absorbed phosphate binder, and has the added benefit of a carbonate filter. The company says in clinical study comparing Renvela to Renagel both controlled serum phosphorus equally to within the recommended KDOQI range.

The company is seeking worldwide approvals for Renvela. The drug has been approved in India, Brazil and the US.

In late May the European Medicines Agency's Committee for Human Medicinal Products adopted a positive opinion on the marketing authorization application for Mozobil. In the EU, Mozobil would be indicated in combination with granulocyte-colony stimulating factor to enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilze poorly.

Genzyme says it plans to submit additional approval applications in up to 60 countries.

Contact: Web site: www.genzyme.com
COPYRIGHT 2009 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Transplant News
Date:Jun 1, 2009
Words:196
Previous Article:Astellas receives approval from FDA for use of Prograf in conjunction with MMF in kidney transplant recipients.
Next Article:FDA grants Tolera Therapeutics orphan drug status for its anti-rejection drug TOL101.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters